{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:57Z","timestamp":1789858137388,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.semarthrit.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T22:00:59Z","timestamp":1478037659000},"page":"584-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review"],"prefix":"10.1016","volume":"46","author":[{"given":"Rebecca","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare E.","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semarthrit.2016.10.008_bib1","first-page":"1520","article-title":"Worldwide prevalence of juvenile arthritis why does it vary so much?","volume":"29","author":"Manners","year":"2002","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2016.10.008_bib2","first-page":"2275","article-title":"Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria","volume":"30","author":"Berntson","year":"2003","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2016.10.008_bib3","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2016.10.008_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.semarthrit.2016.10.008_bib5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/acr.22259","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis","volume":"66","author":"Ringold","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2016.10.008_bib6","unstructured":"Clinical Commissioning Policy Statement. Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis (JIA); 2015."},{"key":"10.1016\/j.semarthrit.2016.10.008_bib7","unstructured":"National Institute for Clinical Excellence (NICE). Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta373?unlid=335659976201612313514\u3009; 2015."},{"issue":"11","key":"10.1016\/j.semarthrit.2016.10.008_bib8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1517\/14712598.2013.840580","article-title":"Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis","volume":"13","author":"Berard","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2016.10.008_bib10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","article-title":"Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis","volume":"50","author":"Papsdorf","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.semarthrit.2016.10.008_bib11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.10.008_bib12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-12-13","article-title":"Treatment of juvenile idiopathic arthritis: a revolution in care","volume":"12","author":"Stoll","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"10.1016\/j.semarthrit.2016.10.008_bib13","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1136\/annrheumdis-2012-201991","article-title":"Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons","volume":"72","author":"Otten","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9783","key":"10.1016\/j.semarthrit.2016.10.008_bib14","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.10.008_bib15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u05f3s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"issue":"7","key":"10.1016\/j.semarthrit.2016.10.008_bib16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2016.10.008_bib18","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2016.10.008_bib19","doi-asserted-by":"publisher","first-page":"SR35","DOI":"10.12659\/MSM.882109","article-title":"Etanercept treatment in juvenile idiopathic arthritis: the Polish registry","volume":"17","author":"Zuber","year":"2011","journal-title":"Med Sci Monit"},{"issue":"4","key":"10.1016\/j.semarthrit.2016.10.008_bib20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/rheumatology\/kes373","article-title":"Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register","volume":"52","author":"Anink","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2016.10.008_bib21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2016.10.008_bib22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2016.10.008_bib23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"9636","key":"10.1016\/j.semarthrit.2016.10.008_bib24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2016.10.008_bib25","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2016.10.008_bib26","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3899\/jrheum.110145","article-title":"Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis\u2014data from the dutch arthritis and biologicals in children register, 1999\u20132010","volume":"38","author":"Otten","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2016.10.008_bib27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/ard.2010.135731","article-title":"Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?","volume":"70","author":"Otten","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2016.10.008_bib28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2016.10.008_bib29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00296-008-0563-2","article-title":"Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years","volume":"28","author":"Tzaribachev","year":"2008","journal-title":"Rheumatol Int"},{"issue":"21","key":"10.1016\/j.semarthrit.2016.10.008_bib30","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2011.1671","article-title":"Factors associated with treatment response to etanercept in juvenile idiopathic arthritis","volume":"306","author":"Otten","year":"2011","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3899\/jrheum.090952","article-title":"Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents","volume":"36","author":"Russo","year":"2009","journal-title":"J Rheumatol"},{"issue":"25","key":"10.1016\/j.semarthrit.2016.10.008_bib32","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De","year":"2012","journal-title":"N Engl J Med"},{"issue":"9617","key":"10.1016\/j.semarthrit.2016.10.008_bib33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.semarthrit.2016.10.008_bib34","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2016.10.008_bib35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","article-title":"Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register","volume":"72","author":"Otten","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib38","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2016.10.008_bib39","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2016.10.008_bib40","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2016.10.008_bib41","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2016.10.008_bib42","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib43","first-page":"871","article-title":"Progression of articular and extraarticular damage in oligoarticular juvenile idiopathic arthritis","volume":"29","author":"de Oliveira","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2016.10.008_bib44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s11926-014-0466-z","article-title":"Enthesitis-related arthritis: time to re-define?","volume":"16","author":"Bryan","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"5 Suppl 93","key":"10.1016\/j.semarthrit.2016.10.008_bib45","first-page":"S40","article-title":"The conundrum of juvenile psoriatic arthritis","volume":"33","author":"Ravelli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2016.10.008_bib46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1586\/eci.10.41","article-title":"Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis","volume":"6","author":"Yokota","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2016.10.008_bib47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2016.10.008_bib48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2016.10.008_bib49","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2016.10.008_bib50","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2016.10.008_bib51","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2016.10.008_bib52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.semarthrit.2012.10.006","article-title":"The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review","volume":"42","author":"Ungar","year":"2013","journal-title":"Semin Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216301536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:11:03Z","timestamp":1749683463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216301536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0049017216301536"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.008","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}